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Abstract
High throughput screening (HTS) facilitates screening large numbers of compounds against a
biochemical target of interest using validated biological or biophysical assays. In recent years, a
significant number of drugs in clinical trails originated from HTS campaigns, validating HTS as a
bona fide mechanism for hit finding. In the current drug discovery landscape, the pharmaceutical
industry is embracing open innovation strategies with academia to maximize their research
capabilities and to feed their drug discovery pipeline. The goals of academic research have
therefore expanded from target identification and validation to probe discovery, chemical
genomics, and compound library screening. This trend is reflected in the emergence of HTS
centers in the public domain over the past decade, ranging in size from modestly equipped
academic screening centers to well endowed Molecular Libraries Probe Centers Network
(MLPCN) centers funded by the NIH Roadmap initiative. These centers facilitate a comprehensive
approach to probe discovery in academia and utilize both classical and cutting-edge assay
technologies for executing primary and secondary screening campaigns. The various facets of
academic HTS centers as well as their implications on technology transfer and drug discovery are
discussed, and a roadmap for successful drug discovery in the public domain is presented. New
lead discovery against therapeutic targets, especially those involving the rare and neglected
diseases, is indeed a Mount Everestonian size task, and requires diligent implementation of
pharmaceutical industry’s best practices for a successful outcome.
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INTRODUCTION
The landscape for discovery of new drug targets in the post-human genome sequencing era
is experiencing record growth, such is not the case for the introduction of new chemical
entities (NCE) against therapeutic targets [1]. Over the last decade, the NCE introductions
per year have been at nearly half the rate from the historical averages. By any account, the
pharmaceutical industry is at a critical juncture at present with the research and development
(R&D) costs escalating by leaps and bounds, and the productivity, as indicated by
independent new drug filings, lagging far behind. This disconnect could be attributed to the
difficulty in translating the disease biology-derived therapeutic target discoveries to the
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discovery and development of chemical probes and their subsequent development as
preclinical candidates.
Drug repurposing, finding novel uses for old drugs, is the new ‘mantra’ for many
pharmaceutical companies. This new endeavor infers that for many targets, there is more
than one drug, and that many drugs are promiscuous, targeting more than one protein. With
more than $50 billion/year being spent on research, it is quite alarming to know that the
pharmaceutical industry could not confidently affirm the selectivity and specificity of the
drugs it markets. The number of US Food and Drug Administration approved drugs target
less than 0.05% of the human genome, a mere 106 genes and 378 targets [2]. However, there
are 4500 disease modifying genes in the human genome which include ~3000 druggable (by
small molecules) genes along with another 10,000 genes that are addressable by protein
therapeutics [3]. This stresses the need to critically interrogate the druggable human genome
to expand the target universe, and to facilitate the discovery of new, novel and safer drugs
with greater selectivity and specificity [4].
Academia has traditionally been involved in understanding the fundamental aspects of
disease biology, the associated biological pathways and identifying the relevant biochemical
targets for therapeutic intervention. This information has eventually led to the initiation and
development of drug discovery projects within the pharmaceutical sector through its project
scouting efforts either independently or licensed from the academic institution. Academia
has evolved in recent years from its traditional role of target identification and validation
from a systems biology perspective to probing for tool molecules (probes) against these
disease targets to explore their therapeutic relevance. Probe discovery has now gained
unparalleled momentum in academia with the availability of vendor-supplied, diversity-
based chemical libraries, and an easy and ready access to on-campus high throughput
screening (HTS) laboratories (Fig. (1)). Academic researchers, who maintain the view that
HTS is an anti-intellectual endeavor, have been experiencing a change of mindset, and have
come to appreciate the importance of HTS in new lead discovery and in the development of
molecular probes as tool molecules. With the flow of top pharmaceutical drug discovery
scientific talent into academia and the commercialization of small molecule library
synthesis, academia is poised to take new lead drug discovery to greater heights. The
challenge that remains to be addressed by academia is in defining the end goal of HTS. Is it
just to find a ‘tool’ molecule, or is it to discover and develop a ‘drug’? What processes and
collaborations have been set in place to transform a hit to a lead? With the ‘publish or
perish’ dogma that is embedded in academia, protection of intellectual property (IP) rights is
a formidable task even if one finds the proverbial needle in a haystack. Technology transfer
offices in academia continue to experience difficulty in licensing these molecular probes to
pharma at very early stages of medicinal chemistry explorations. There is a heightened
awareness for better understanding of the changing landscape at the pharma-academia
interface, the role of academia in translational research and what constitutes a win-win
scenario for technology transfer, and to strengthen opportunities for close collaboration
between pharma and academia.
DRUG DISCOVERY AND MARKET RISK
All diseases occupy a position in the discovery/market risk-space that guides pharmaceutical
industry’s drug discovery and development endeavors. The balance between risk and reward
can determine the investment and priority of a project for a given institution or company [5].
The risk of a drug discovery project can be measured by the likelihood of success, return on
investment, or potential for passing clinical trials. The reward for a project is dependent on
the impact of the probe against the target, or the size of the affected patient population. The
market risk increases with small patient populations and decreasing financial return
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projections; and the drug discovery risk increases as targets become unconventional and
uncertain. Economic considerations constrain pharma to a low risk territory and focus on
proven targets in diseases with large patient populations. The dynamic between these
variables and their interplay for public and private domain drug discovery projects is
displayed in Fig. (2) a hypothetical generalization of the relationship between risk and
reward against investment. The private domain screening campaigns tend to focus more on
low risk projects against known targets, with large potential rewards, targeting diseases
affecting a large percentage of the population like cancer and heart disease. The academia
driven by government incentives [6], and partly by societal obligation, has stepped in to
fully cover the discovery/market risk-space, as illustrated by small, upper grey dots in Fig.
(2). Although the academic research on the basic and clinical aspects of orphan diseases can
provide the industry with druggable targets, further labor and cost-intensive development of
potential leads into drugs coupled with low market returns may not hold industry’s interest
in these areas. A partnership between the public, philanthropic and private sectors is viewed
as a means to bring down the costs and market risks and to stimulate drug discovery in the
orphan disease area.
NIH ROADMAP INITIATIVE
The complete sequencing of the human genome demonstrated that cutting-edge technologies
can effectively be used in successfully addressing problems that were considered to be
insurmountable just a decade ago. Using the Human Genome Project as an example, the
NIH Roadmap Initiative was launched in 2005, enacted into law by Congress through the
NIH Reform Act. The Roadmap Initiative sought to stimulate high-risk, interdisciplinary
research facilitating translation of basic research discoveries into drugs, treatments, or
methods for prevention. The NIH Molecular Libraries Roadmap [7] established three
primary components toward furthering novel probe development in the public domain: (1)
screening and data production, (2) data analysis and dissemination, PubChem, and (3)
technology development (Fig. (3)).
The initial pilot phase of the Molecular Libraries Program (MLP), Molecular Libraries
Screening Centers Network (MLSCN), consisted of ten screening centers with no significant
medicinal chemistry component, and has entered into a full-fledged production phase, the
Molecular Libraries Probe Production Centers Network (MLPCN), whose primary goal is to
generate small molecule probes against therapeutic targets of interest by executing
investigator-developed HTS campaigns, secondary and counter screens, cheminformatics,
and SAR through directed medicinal chemistry efforts. The MLPCN has four
comprehensive centers (NIH Chemical genomics Center (NCGC), Sanford-Burnham,
Scripps and the Broad Institute), three specialized screening centers (University of New
Mexico, Southern Research Institute and Johns Hopkins), and two specialized chemistry
centers (Vanderbilt and University of Kansas) (Table 1). The NIH R03 application
mechanism is the process by which awardees can gain access into the MLPCN program of
HTS-ready assay development, screening, chem.-informatics, medicinal chemistry and
probe development, all paid by the MLP. The progress of an assay to and through the
MLPCN follows a critical path of steps containing cutoffs for potency, dose response, and
selectivity (Table 2). The MLPCN has a library of 500,000 chemically diverse small
molecules which have either known biological activities or the potential to modulate novel
biological functions. The MLPCN is a pharmaceutical- industry style (and strength) drug
discovery operation that is focused on new and novel therapeutic targets associated with rare
and neglected diseases that are, for the most part, not being worked on by the
pharmaceutical sector because of its discovery- and market-risk averse posture. Of special
importance is the introduction of quantitative HTS (qHTS) paradigm, a titration-based
approach that efficiently identifies biological activities in large chemical libraries. The
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traditional HTS approach tests compounds at a single concentration, and is burdened by
frequent false positives and false negatives, and requires extensive follow-up testing. To
alleviate this problem, NCGC has developed the qHTS paradigm [8], where every
compound is tested at multiple concentrations to generate concentration-response curves,
classified according to the quality of fit to the data, the number of asymptotes and response
efficacy, in an efficient and cost-effective manner, and demonstrated the feasibility of qHTS
for accurately profiling every compound in large chemical libraries. The qHTS approach
produces rich data sets that can be immediately mined for reliable biological activities,
thereby providing a platform for chemical genomics and accelerating the identification of
leads for drug discovery. While the efforts at NCGC are impressive, the fact remains that
high throughput screening of random/diverse chemical libraries generates null data sets
since HTS is a binary modality in identifying about 99.9% inactives and 0.1% actives. The
increase in concentrations of qHTS is severely cost-inhibitive, as the cost of running a qHTS
campaign is at least an order of magnitude greater than the traditional HTS campaigns where
compounds are tested at n=1.
PubChem
One major benefit of the NIH Roadmap Initiative was the results sharing process, afforded
through the public online database PubChem (pubchem.ncbi.nlm.nih.gov/). PubChem is an
expansive database of chemical structures and their biological activities, developed by the
National Center for Biotechnology Information at NIH. PubChem holds both compound
information from the scientific literature as well as screening and probe data from both the
MLSCN and the MLPCN, and from NIH-supported HTS campaigns carried in academia.
This compound information storage platform gave new insight into compound selectivity or
promiscuity, as these open access drug discovery databases provided comparative
information across the hundreds of screens and bioassays to show which compounds were
actives in which high throughput screens. PubChem gives researchers the ability to search
bioassay records and chemical structures, and provides links to active compounds and
bioassay results, as well as available biological property information for compounds. This
tool brought together the results of the ten MLSCN HTS institutions, and the current
MLPCN into a single, comparative system available to the public. The Pub-Chem database
now lists almost 1900 HTS programs of various sizes, 1300 bioassays, over 37 million data
points against 171 molecular targets. ChEMBLdb, the European counterpart of the
PubChem, lists 2.4 million records, and provides information on the properties and activities
of over half a million drugs and drug-like molecules and their targets. The NIH roadmap
initiatives along with the MLSCN-/MLPCN programs have identified over 93 probes with
submicromolar potency, which amounts to be approximately $6.2 million per probe,
illustrating the enormous difficulty in identifying probes against novel therapeutic targets
(Table 3) [9]. One could also attribute this to the inefficiency in coordinating therapeutic
biology with medicinal chemistry, a rare combination of skills in the biomedical science
community which is more biology-oriented.
Eu-OpenScreen
One of the most ambitious open access high throughput drug discovery platforms in the
public domain, EU-Open-Screen, an European counterpart for United States’ NIH Roadmap
initiative, is being coordinated by Dr. Ronald Frank, Leibniz-Institut für Molekulare
Pharmakologie, Berlin, Germany, under the auspices of the Capacities Programme of the
European Commission (www.eu-opens-creende). It is open to all European organizations
involved in Chemical Biology, and the current participation includes a total of 19 academic
and non-profit institutions from 17 European countries, and brings together biomedical
scientists representing all related and required disciplines. This will be an association of
HTS centers across Europe, and offers resources for executing high throughput screens for
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hit discovery and optimization, bio-and chemoinformatics support, and a publicly accessible
database, analogous to PubChem, the latter providing screening results, assay protocols and
chemical information. The chemical library, representing the chemical knowledge of
Europe, will be housed in a central location. The Eu-OpenScreen, a transnational venture
and much broader in scope than the NIH Roadmap initiative, will provide European
researchers access to the most advanced screening technologies and support projects on
unconventional targets that address fundamental biological questions in all disciplines of
Life Sciences. A much thought out framework for IP management is integral to the Eu-
Open-Screen operational infrastructure, thus ensuring rapid knowledge sharing and
commercial exploitation of gained knowledge.
ACADEMIC HTS CORE FACILITIES
Within the past few years, academia has jumped into the arena of probe discovery in a rather
big way, and started setting up medium and high throughput core screening facilities with
needed instrumentation and expertise, which used to be the forte of the pharmaceutical
industry enterprise [10]. A number of key factors have influenced this transformation,
including the availability and price of compound libraries, equipment, and technology. For
libraries, there is a wide array of vendor-supplied, high quality, diverse chemical libraries. In
addition to decreasing prices for libraries, the market has seen a maturation of automation
equipment including liquid handlers and laboratory robotics, screening and signal detection
technology platforms including reagents and instrumentation. Most importantly, there is a
flow of pharmaceutical industry talent into academia, aided by the huge lay offs undertaken
by pharma in its desperate cost cutting ventures to boost its profitability margins [11].
Dedicated academic HTS centers are equipped with compound libraries on the order of
100,000 compounds or greater, and possess a variety of 96/384-tip liquid handlers, bulk
liquid dispensers, and multi-format plate readers (Table 4). These HTS labs have the
capacity to address multiple assay methodologies [12]. Public domain screening efforts are
limited to medium or high throughput, with the exception of the NCGC, an ultra high
throughput screening (uHTS) center. The NCGC uses a Kalypsys High-Throughput Robotic
Screening System to perform ultra high throughput screens in 1536-well format, pushing
throughput up to a million wells/day.
Unfortunately, the NIH Roadmap Initiative supports its own network centers with no
support provided to the other HTS centers in academia. This is reflected by the fact that
most academic HTS facilities, compared to those in the pharmaceutical industry or NCGC,
suffer immensely from a lack of public funding. Academic HTS is also hindered by a lack of
integrated robotic screening platforms, and compound collections are modest with no
institutional medicinal chemistry collections being part of the chemical library holdings.
Further, academic HTS data analysis software tends to be home-grown and strewn together
by open source programs and lack the sophistication needed in carrying comprehensive data
analysis routines.
While most academic HTS core facilities are for exclusive use by its own institutional
investigators, some institutions (for e.g. the University of Kansas) have broadened their
reach by opening the doors to investigators from institutions, both public and private, where
a state-of-the-art HTS infrastructure may not be available [13]. While these core facilities
are primarily a fee-for-service operation, the main goal of these facilities is to see the
investigators succeed in their probe discovery endeavors, and for which they contribute
intellectually above and beyond what was originally conceived in setting up these facilities
[14].
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Drug discovery research is often termed as searching for a needle in a haystack. Large
compound libraries, corporate chemical archive databases, virtual compound collections and
chemical library supplier’s databases are routinely screened, either in the laboratory or in
silico, for drug candidates. This endeavor is worse than finding a needle in a haystack, as we
do not exactly know the size or shape of the needle. We have very limited knowledge about
the chemical probe, the needle, that we need to find. Often we do not know how it looks or
even if it is there or not. However, there is a distinct possibility that we may end up finding
more than one. After exhaustively picking all of the low hanging fruits, the pharmaceutical
industry has invested heavily in HTS technologies and the robotic platforms to screen
millions of compounds, both corporate as well as vendor-supplied collections. Although
academia has increasingly ventured into the arena of HTS, its end goal remains undefined
beyond publications and garnering extramural funding. In academia, not MLPCN, the
involvement of medicinal chemistry in taking screen hits to the level of bona fide probes still
remains at large. The concept of medicinal chemistry as an unbroken continuum of HTS
efforts, as has long been the case in pharmaceutical industry, stills needs to be anchored into
the mindset of academia.
Target Identification
The human genomic sequence is being probed in academia and industry using genomics,
proteomics, small interfering RNA (siRNA) and mouse knockout models for identification
and validation of disease-relevant targets [4, 15, 16]. The strength of the academic
investigators lies in target identification, validation and elucidating the mechanistic aspects
of therapeutic drug targets, and it is primarily done in the investigator’s own laboratory.
While it is perceived that academic investigators conduct cutting edge research, it is all too
common that they do not necessarily employ cutting edge tools in driving their research
because of budget limitations, sheer lack of interest, or knowledge. If academia wants to
explore the large repertoire of undrugged targets in the most efficient manner, the principal
investigator (PI) should partner with the HTS facilities in designing innovative assays
towards target identification and validation, as well as to screen these novel targets which
can be used in discovering bona fide probes. For instance, academic investigators can
effectively take advantage of increasingly affordable and commercially available human and
mouse genome-wide siRNA libraries toward target identification using institutional HTS
labs. In addition, several smaller siRNA sub-libraries are also available for screening at
various HTS centers. The University of Texas Southwestern Cancer Center HTS Laboratory
allows the academicians to perform high-throughput screening of genomic siRNA libraries.
The HTS Bioscience center at Stanford university has siRNA screening sets divided into
GPCR (517 genes), kinase (779), drug-gable genome (6022), and the remaining genome
(13,804) for a total of 21,122 targeted genes (http://htbc.stanford.edu/htmolbio/sirna.html).
The genes identified in HTS experiments are potential novel targets [17] for compound
screens leading to probe discovery.
Screening Technologies
The successful completion and execution of drug discovery projects require the alignment of
the capabilities of the HTS center with that of the incoming projects. The HTS center
interacts with technologists, chemists and biologists to develop more productive screening
projects. The academic screens encompass a wide variety of targets and associated assay
formats, and the academic HTS centers are equipped with a wide range of detection systems,
such as luminescence, fluorescence, FLIPR, FRET, absorbance, ELISA, microscopy-based
imaging, and small molecule microarray (Table 5). There are many academic centers that
focus on one or more specialized technologies. The ability to perform miniaturized
biological assays in 384-well and 1536-well format is no longer limited to the private sector.
Public domain HTS centers have many of the same capabilities and technologies as pharma,
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enabling equal capacity for pre-screen basic research, elaborate secondary and tertiary
screening, and the ability to elucidate mechanism of action (MOA). These capabilities cover
a wide range of biologies including enzyme targets, GPCRs, ion channels, transporters,
protein-protein interactions, protein misfolding and protein degradation. The ability to
address MOA and tertiary screens are handled easily by public domain through a diverse set
of screening platform technologies, including high content screening (HCS), high-
throughput microscopy and high content analysis (HCA), flow cytometry, HTS and ultra
HTS, NMR-based methods, and access to BSL-3 level laboratories.
Several screening centers have taken extra measures to stand out and have developed novel
screening platforms. For example, the University of New Mexico Center for Molecular
Discovery is a specialty screening center focusing on multiplexed, high throughput flow
cytometry approach to identification of small molecules that bind to cellular receptors and
modulate clinically therapeutic cellular responses. The center has a customized screening
platform called HyperCyt which enables sampling throughput rates of 40 samples per
minute [18] for the measurement of particle fluorescence at the single-cell level. The
technique is very sensitive, allowing real-time detection of 10–100 pM fluorescent
molecules on a cell or a bead. The assays are homogeneous and do not require wash steps
since the laser excites a very small volume surrounding the cell and limits the excitation of
unbound fluorescent molecules.
Public domain HTS centers are the focal points for familiarizing the new technology-shy
academic investigators with breakthrough technologies, yet very few embrace label-free
(cell-based and cell-free) assay formats and other very powerful technology platforms.
Currently, the majority of the HTS assays rely on labels of some sort (luminescent,
fluorescent or radioactive) to monitor cellular responses and to quantify biochemical
reactions. Conventional label and reporter-based cell assays are often prone to artifacts due
to perturbation of the native cellular environment, either by the label or by over-expression
of the target or the reporter protein. The labels can have adverse effects on binding
interactions, leading to false or misleading conclusions about binding properties of screening
hits. For this reason, label-free technologies are especially ideally suited for use with cell-
based screening or hit-to-lead optimization platforms.
Label free detection platforms, such as Corning’s Epic, Sru Biosystems’ Bind and Roche
Biosciences’ xCelligence systems, can serve important roles in primary screening as well as
lead optimization, and should be seriously considered in academic settings. Many cellular
processes including proliferation, migration, adhesion and apoptosis are associated with very
specific and well-defined changes in cell morphology and adhesion. All of these changes are
measured by the label-free technologies utilize the biophysical properties to generate a
quantitative functional output for various cellular outcomes including cytotoxicity, receptor-
mediated signaling, cell migration, cell adhesion, etc. These techniques alleviate the need for
cellular labeling or over-expression of reporter proteins, and allow real-time kinetic
measurements in native and physiologically relevant cell environment. The label-free
technologies can measure changes in impedance as cell grow in plates armed with gold-
electrodes (Roche’s xCELLigence system) or can measure changes in refractive index
(Corning’s Epic) [19]. Some technologies utilize acoustic or fiber-optics to measure changes
in cell morphology or size. The label-free technologies can be fairly flexible and therefore
allow for rapid assay optimization and development. In primary screenings, label-free
technologies reduce the number of false positives or false negatives. In lead characterization
stages, the dynamic monitoring of cellular events can be used to obtain signature patterns or
profiles for compounds with similar mechanisms in long-term cytotoxicity assays. Surface
plasmon resonance (SPR) technology is another powerful label-free technology platform for
monitoring interactions between low-molecular-weight molecules and target proteins [20].
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The binding affinity measurements from SPR can be used for hit identification and profiling
when working with targets of unknown function or in the absence of a functional assay. SPR
technology therefore has a place in both primary screenings as well as lead characterization
stages of high throughput drug discovery campaigns.
Protein-protein interactions, stable or transient, are at the core of almost every metabolic
pathway, and in cellular responses to extracellular signals. As such, it is an area of great
interest for therapeutic intervention. Protein-protein interactions between an antibody and
antigen have been used successfully in development of biologics that are highly specific and
efficacious. Despite their high costs of production, the biologics comprise a major share of
the market and are currently used in treatment of cancer, immune disorders, etc. The major
challenge in obtaining orally available, small molecule drug-like compounds lies in defining
surfaces and residues involved in intracellular protein-protein interactions [21, 22]. In vast
majority of cases, designing small molecules to antagonize interactions at the hot spots
specifically is very challenging and requires knowledge of stoichiometry, binding sites,
number of interaction partners and fluidity of interacting surfaces. The yeast two-hybrid
system is one of the most popular techniques available for identifying protein-protein
interactions in vivo. Enzyme-linked immunosorbent assays (ELISAs), fluorescence
polarization (FP), and SPR have also been applied in a HTS mode for the identification of
small molecule modulators of protein-protein interactions, albeit with much less success.
AlphaScreen® and AlphaLISA® are powerful reagent platforms that utilize Perkin Elmer’s
proprietary bead-based Alpha technology can be applied in HTS mode to screen for protein-
protein interaction modulators [23]. Multiangle, time-dependent, static light scattering is a
powerful technology platform for probing and identifying small molecules that affect
protein-protein interactions without the need for labeling, immobilization, substrates,
cofactors, etc. Because of the therapeutic relevance of this important area, academic HTS
laboratories can make important contribution by evaluating and eventually embracing the
most robust technology formats that is HTS amenable.
Advances in automated microscopy hardware and image acquisition and analysis software
have led to a boom in high throughput microscopy [24], and their incorporation into cell-
based screens to produce high content screening (HCS). By automating the process of image
capture and analysis, HCS can be applied to hundreds of microtiter plates, enabling the
automated analysis of millions of individual cells in tens of thousands of samples, to fit the
high throughput microscopic analysis needs of drug discovery and systems cell biology. The
prevalence of fluorophores and labeled antibodies, biosensors, and environmentally sensitive
probes and stains, fluorescence microscopy can be applied through high content analysis
(HCA) to many drug target classes. HCS can be applied with multiple filter sets and
confocal microscope capacities, allowing simultaneous multiple target readouts, or
multiplexing, and can provide subpopulation analysis on groups of uniquely affected cells in
a larger population. Thus the “content” of high content screening refers to the wide amount
of multi-parameter quantitative and qualitative information collected, as compared to single
parameter target data of standard biochemical and cell-based high throughput screen. The
multiplexing aspect of HCS allows researchers to study both the target effect of a primary
screen while collecting data for tertiary effects for elucidating the MOA of a compound [25].
Importance of Secondary Screens
While academia has made great strides in implementing HTS campaigns for hit finding, the
relative importance of secondary screens in affirming selectivity and specificity of the
primary screen actives has not been given a fair share or a serious consideration as a
continuum of the front end of the probe discovery effort. The hit to lead optimization efforts
aim to turn this overwhelmingly large and varied collection of molecules into a manageable
number of compounds which can serve as starting points for the lead optimization process
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[26]. The process involves subjecting each molecule to a series of robust and rapid
secondary assays to assess compounds for lead-like properties and identify ones that have a
high likelihood of success in pre-clinical and clinical phases of drug development. The
secondary screens ought to include counter-assays that address cytotoxicity, permeability
and metabolic stability, such as HERG inhibition, Caco-2 permeability, CypP450 inhibition
and virtual screenings. Identification of meaningful assays that help establish a direct
relationship between the target and the compound activity are vital to the success of hit to
probe to lead identification and optimization. These counter-assays are designed to ensure
that significant time and effort is not wasted on chemotypes with intrinsic liabilities at later
stages of lead optimization.
Grant Application Support
An important aspect of the function of HTS core facilities is to support PIs in their efforts to
garner extramural funding. An obligatory function of the HTS staff is to provide letters of
support that outline a strategic approach for choosing assay design specifics. HTS staff also
performs assay development, generating quality preliminary data with acceptable statistical
parameters, and draft necessary secondary and counter screens to ascertain selectivity and
specificity. The HTS staff collaborates in submitting PIs grant applications geared towards
NIH Roadmap initiative supported R21 (PAR-08–024) mechanism- assay development (not
HTS ready) for high throughput molecular screening (http://grants.nih.gov/grants/guide/pa-
files/PAR-08–024.html), R03 (PAR-09–129) mechanism-development of assays which are
screening ready and implementation in one of the MLPCN centers, (http://grants.nih.gov/
grants/guide/pa-files/PAR-09-129.html), and Fast Track Entry (NOT-RM-09–011)
mechanism by bootstrapping an existing R21 that is ready for screening, or an R01 which
has some type of screening context in the application for screening in one of the MLPCN
centers (http://grants.nih.gov/grants/guide/notice-files/NOT-RM-09-011.html). In addition
to these NIH sponsored granting mechanism, HTS staff is actively involved in supporting a
number of other funding opportunities including those from non-NIH governmental
agencies and not-for-profit disease foundations. It is to the benefit of the PI to make the
application a relatively strong one by having HTS staff as Co-PIs or collaborators. Pre-grant
mentoring is another important function of the HTS staff as well. This would include advice
on 1) deciding between an R01, R03, or R21 submission, 2) opting for core facilities on a
fee-for-service basis, 3) cutting edge tools and assay formats for formatting investigator’s
bench-top assay for the high-throughput environment, and 4) the amount of preliminary data
required.
Improving Science through HTS Consultation
A typical public screening center commonly receives dozens of requests for screening
collaborations. However, many of these collaborations are from labs with no experience
with the stringent quality control requirements of HTS, and often, there are new assay
systems that may be more ammenable to HTS but not known to the investigator (Fig. (4)).
The collaboration of a PI with an HTS lab can lead to a positive outcome as science is
improved through consultation. A recent client of the KU-HTS core proposed a multistep
lactate dehydrogenase (LDH) assay in a 12-well plate format for a cell-based screening
project. The HTS lab miniaturized the assay down to 384-well format, cutting well size by
1/32 and cutting costs by decreasing reagent use. Consultation with the HTS lab revealed
that an alternative assay system would be more prudent for the client’s work. Upon studying
the science related to the cell biology being tested, the measurement of cytotoxicity or
viability would be equally important for evaluating compound efficacy. The HTS lab then
compared five different assays head-to-head simultaneously to determine which assay was
more suitable for a client’s HTS needs: (1) a heterogeneous cell viability assessment, (2) a
heterogeneous absorbance-based LDH assay, (3) a homogenous absorbance-based LDH
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assay, (4) a fluorescent cytotoxicity assay, or (5) a luminescence cyto-toxicity assay. The
homogenous assays proved to be more suitable for HTS than the client’s multistep
heterogeneous assay. The cell viability assay was also able to inversely measure cytotoxicity
by the remaining cells, as directly compared to the client’s cytotoxicity assay. The simplicity
of the homogenous cell viability assay allowed for dramatically fewer handling steps,
allowing the procedure to be miniaturized to 384-well and automated using bulk liquid
dispensers and robotic automated liquid handling instruments.
Strengthening Public Domain HTS through Industry Best Practice
Industry has spent decades learning the best ways to increase output through teamwork
among multiple research cores, towards a single common goal. In recent years, academia
has moved away from the individualistic approach of prior generations toward this same
interdisciplinary approach. The KU HTS lab plays an active role in applying industry best
practice to its collaborations, due to experienced project mentorship. The HTS director and
project managers have many years of experience in the pharmaceutical industry, and
commandeer teamwork to unify efforts across multiple labs and cores. This management
was recently applied on a project spanning 20 cancer cells lines from 5 different research
groups, using at least four different assay methods to measure efficacy of potential
anticancer compounds. To evaluate a novel panel of compound analogs, the project
management team consulted with the lead investigators from each research group and
decided on a key assay platform that would accommodate each investigator’s needs. The
compound panels were evaluated using a homogenous cell viability assay using newly
purchased cell lines from ATCC in a miniaturized 384-well plate format. Rather than use
cell lines from individual labs, the cell lines were purchased from ATCC to follow MTA
agreements with ATCC. This assured the origin and handling of each cell line, and avoided
potential problems that occur from long-term passaging of cells, such as contamination with
other cell lines (contaminating cell lines with Hela cells), and to prevent importing
mycoplasma or other contaminants from the collaborating labs. A quantitative ATP assay
was used to replace the various labs’ methods of quantifying cell viability and cytotoxicity,
in a manner that allowed 384-well format miniaturization and assay automation. The
investigators agreed that the ATP assay was more suitable to the high throughput
measurement of cell viability due to its sensitivity, simplicity, speed, flexibility, and signal
stability. The entire panel of cell lines was cell banked, and optimal seeding density was
determined for each to assure assay uniformity from cell line to cell line. The cytotoxicity of
the analogs was determined at multiple concentrations using the panel of 20 cell lines. The
results of the studies enabled the rank ordering of each compound for cytotoxicity in
multiple cell lines in parallel. The cell growth inhibition data revealed both the most potent
compounds and the most sensitive cell lines. The mutual agreement across labs for a unified
HTS project applied to a wide assortment of assay conditions and cell lines provided
comparable data across the cell lines. This project was heavily dependent on strong,
industry-style management.
HTS Data Management
The pharmaceutical industry has expended enormous amount of resources, both in
manpower and software, towards data storage, analysis, and management. In addition to the
experimental data, the data management system handles information on chemical library,
stocks management, compounds and their molecular structures and descriptors, and allows
efficient structure similarity searches against internal or commercial libraries. In the early
days of screening, home-grown software ruled the day. But in the past few years, vendor
solutions have become more robust, giving organizations viable alternatives to building and
maintaining systems themselves [27]. A number of commercially available data
management systems like the Pipeline Pilot scientific data workflow platform (Accelrys)
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and Activity base XE (IDBS) enable custom data processing applications. Many of the
databases can be queried using accessory modules provided by Spotfire or MDL systems.
To achieve successful integration of metadata for all compounds and to provide a context or
direction to assist medicinal chemists and others with interpreting and acting on screening
results, pharma is partnering with software companies to customize software for
consolidating data from isolated databases. Such partnerships are seen in Amgen Lead
Discovery Informatics between Amgen and Genedata, which allows integration of
voluminous data from Amgen’s screens and the Next-Gen Discovery IT between Tripos and
Wyeth (now Pfizer), have a patented method of characterizing the structural diversity of
large combinatorial libraries with information located in their disparate databases.
While large pharmaceutical companies and well-endowed establishments can afford high-
end oracle-based sophisticated data management tools, most universities and institutes rely
on alternative measures for data storage and management. Many HTS centers have
developed their own data management systems utilizing the services of their affiliated
information technology services. The M-screen at University of Michigan and K-Screen at
University of Kansas are examples of indigenous data management systems, but these
neither have the requisite sophistication, speed or breadth needed in managing HTS data,
and to allow timely comparison of activity profiles across screens. The NIH Roadmap
supported comprehensive screening centers including NCGC employ sophisticated data
analysis tools, and a mechanism needs to be developed and instituted to bring up to speed
their brethren in the rest of the academia.
Probe Discovery and Development in Academia
The word "probe" is a broad term which can be interpreted to mean any one of a wide
variety of agents. These include active chemistries discovered in academic screening labs or
in government (MLPCN or the NCGC), commercially available probes (i.e. dyes,
antibodies, fluorescent proteins), failed drug candidates from pharma, whole body or cellular
imaging agents, specific biomarkers or tool molecules from chemigenomics and/or systems
biology efforts. The probes are designed to interact with the biological (biochemical) target
of interest rather selectively and help explore the role of the target in a systems biology
context. A high quality probe is expected to have proven chemical identity, highly potent
with selectivity and submicromolar affinity towards the target in vitro, efficacious, a
sigmoidal dose-activity relationship within two orders of the tested concentration range with
nH=1, best in series with a reasonable set of congeners to develop QSAR profiles suggestive
of target selectivity, and be functionally active in a cellular system (minimally) to link target
biology with disease biology under study. It is not necessarily be drug-like, adhere to
Lipinski rule of 5 principles, clear ADME/T profile, or have a clear path to IP rights.
Likewise, probes are not to be confused with those identified from a systems biology
approach including those that are active in high content or phenotypic assays where
integrated pathways are interrogated. In our opinion, a bona fide probe has to be either
specific or selective at the biochemical target level (Table 6).
The success of any high throughput screening campaign in finding a target-specific probe is
dependent to a large extent on the assay design and on the quality of the chemical library.
While the assay design is target-specific and the academic investigator has invested his/her
lifetime in this arena, the chemical libraries at the academic HTS centers, without exception,
have been assembled from commercial sources and are modest in size. The compound
libraries are typically composed of purchased, screen-friendly, library sets such as the
LOPAC (Sigma), ChemBridge Corp. (San Diego, CA), Prestwick (Illkirch, France),
MicroSource (Gaylordsville, CT), and ChemDiv, Inc. (San Diego, CA). Despite the fact that
many FDA approved drugs like erythromycin, paclitaxel and doxorubicin were derived from
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natural products, and that almost 50% out of the 877 small-molecule New Chemical Entities
(NCEs) introduced between 1981 and 2002, were natural products or their analogues, there
has been no significant interest within the academic HTS centers to include natural product
libraries as part of their chemical archives.
The end goal of the HTS efforts in academia and the unprecedented investment by the US
Federal Government through the NIH Roadmap Initiative is to find bona fide probes against
disease relevant drug targets. The question that still remains to be answered, rather critically,
is whether academia has the ability, both infrastructure-wise as well as commitment-wise, to
reach the end goal, above and beyond the acquisition of grant funding, publications, and the
holistic exercise of HTS. By any measure, the jury is still out in rendering its verdict. From
the pharmaceutical industry perspective, the front end of drug discovery requires an
interdisciplinary approach involving molecular biologists, cell biologists, biochemists with
HTS ready assay development experience, specialists in automation, robust data analysis
and cheminformatics tools, molecular modelers, medicinal chemists, and project
coordinators to bring the key players from all the disciplines together to facilitate informed
go or no-go decisions on a project in the most efficient way. This concept of integrated,
matrix-team oriented collaborative effort is almost foreign to much of academia. To make
drug discovery in academia a reality, we desperately need the pharmaceutical industry’s best
practice to make drug discovery in academia a reality. Institutions such as the Institute for
Advancing medical Innovations at University of Kansas and the Pennsylvania Center for
Drug Discovery, have taken a lead in this regard. The IAMI has implemented
pharmaceutical industry’s best practices to identify, advance and commercialize IP, and has
created a highly collaborative, entrepreneurial environment which attracts other academic
institutions, industry and disease-focused non-profit organizations into partnership with the
KU.
Industrialization of chemical library synthesis has revolutionized the HTS concept with the
vendor-supplied chemical libraries forming the backbone of academia’s drug discovery
efforts. While institutional chemistries are the jewels of pharmaceutical HTS operations, the
legacy compounds from the institutional medicinal chemistry departments seldom progress
to the chemical archives of the academic HTS centers. One of the most disconcerting aspects
of HTS operations in academia is the inefficiency in coordinating therapeutic biology with
medicinal chemistry, a rare combination of skills in the biomedical science community
which is more biology-oriented. In fact, of the two dozen academic HTS centers in the
United States, only three have institutional medicinal chemistry departments (University of
Kansas, University of Minnesota, and University of Pittsburgh). The University of Kansas
benefits from an integrated medicinal chemistry core to help support the probe discovery
efforts. In the absence of concerted medicinal chemistry involvement, the academic HTS
operations are rather an exercise in futility, which was apparent in the MLSCN phase of the
NIH Roadmap initiative where there was minimal medicinal chemistry involvement.
Contrary to the situation in academia, the HTS operations in pharma are designed and
destined for success as random library screening is actively supported with focused libraries
as well as iterative synthetic support by experienced medicinal chemistry teams. For HTS
operations in academia to be successful, we need the pharmaceutical industry’s best practice
of sourcing as well as optimization of the chemistry.
Medicinal chemistry involvement at an early stage of drug discovery is essential since the
screen actives, in general, are neither selective not potent against the therapeutic target, and
requires iterative synthesis efforts to bring forth an increase in potency by 2 to 3 orders of
magnitude, and a plethora of counter/secondary screens to navigate the synthesis efforts in
achieving target site selectivity [28]. For the academic drug discovery initiatives to succeed,
expert medicinal chemistry is therefore critical. There are 143 well defined substituents
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reported in the literature. If we use all of them in just three positions, we would have 1,433
or 2,924,207 possible compounds. An experienced medicinal chemist might consider
making a drastic structural change, based on historical perspective, prior hands-on
knowledge, and cheminformatics. It is in this area that the academic drug discovery
programs are at their weakest due to lack of adequate medicinal chemistry support. The drug
discovery and development initiatives at academic institutions such as University of Kansas
and the Pennsylvania Center for Drug Discovery present a unique model for fostering a
matrix team approach. This approach is based on a pharmaceutical industry-based best
practice, bridging the gap between in vitro drug target screening and chemical probe
development so as to make drug discovery in academia a reality.
Open Innovation in Lead Discovery
Using the paradigm ‘a problem shared is a problem solved’, open innovation has taken a
strong hold within the last few years in reinvigorating the pharmaceutical R&D endeavors.
This is a shift from ‘innovation within the corporate walls’ concept to the acquisition of IP
from outside the corporate walls to advance its business models, a concept that literally
admits as well as advocates the fact that a problem shared is a problem solved.
Pharmaceutical companies have traditionally safeguarded their own interests and eliminated
competition by stringent IP protection. With the goal of speeding innovative drug discovery
by tapping into global wealth of knowledge and expertise, big pharma is opening up
information flow to public domain and is aggressively establishing new R&D structures to
foster open-innovation strategies up with academia [29]. Such collaborations are
advantageous to both academia and industry. Academia and universities receive more
research dollars for innovative projects, greater involvement for faculty in drug discovery
process as well as a secure path to product development and licensing processes. Pharma
gains novel and relevant targets to feed its pipeline as well as new molecular probes for lead
optimization processes [30]. As shown in Table 7, some such collaborations include
Novartis Institutes for biomedical Research to discover and develop drugs for a range of
inadequately treated diseases, GSK’s Centre of Excellence for external drug discovery,
Pfizer’s Biotherapeutics and Bioinnovation Center, Lilly Melbourne Academic Psychiatry
Initiative for advancing mental health research and education in Australia, and a $14 million
investment by Pfizer at the University of California (Santa Barbara, CA), Caltech, MIT and
University of Massachusetts and Entelos, a physiological modeling company, to re-examine
the regulatory mechanisms of human energy metabolism, and hence expand the
understanding diabetes and obesity pathobiology. Merck has created a virtual department,
External Basic Research, to foster partnerships with academic and biotech collaborators to
identify and access novel targets, using a shared risk paradigm to deliver preclinical
candidates for its pipeline. Burnham is collaborating with J&J on a multi-year assay
development and licensing deal by granting exclusive access to its high-throughput assay
screening technologies, in order to determine potential targets for new drugs against
inflame-matory diseases, such as arthritis and lupus. J&J has also established two
partnership-focused units to ensure the continued nurturing of early academic research
(COSAT) and facilitate translational or applied research toward drug development (eRED).
Together, J&J and academia have a unique opportunity to create an enduring partnership
that will accelerate the introduction of innovative medicines. One of the most impressive
open access drug discovery partnerships was by UK’s Wellcome Trust through a 5-year
Seeding Drug Discovery Initiative (SDDI) in 2005 to facilitate the discovery and
development of drug leads to fill the unmet medical need gap. It has awarded over $135
million to 30 institutions supporting 30 drug discovery projects, and has resulted in access to
recognized experts in the field, dozen patents and three candidates in various stages of
clinical trials. The partnership complemented the lack of pharmaceutical expertise of the
academic investtigators by providing project management oversight, and provided enormous
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cost savings as there was no need to develop infrastructure for each of the novel drug
targets. A recent review of the SDDI program has indicated the academic collaborators’ lack
of medicinal chemistry experience to be a major gap, thus confirming our assertion that
biomedical researchers tend to me more biology-oriented, and that coordinating therapeutic
biology with medicinal chemistry in academia requires an efficient matchmaking by
experienced project coordinators, an Industry best practice.
Open innovations also include Lilly’s Phenotypic Drug Discovery Initiative (https://
pd2.lilly.com/pd2web), in which the compounds synthesized in academia are screened
against phenotypic and other relevant assays optimized in Eli Lilly. While Lilly provides all
evaluations and data free of charge and both the investigator/institution retains IP rights to
the molecule, with Lilly seeking first rights for IP licensing and/or refusal. Merck has
created SAGE, an open access, non-profit, organization to bring academia and pharma
together to develop comprehensive human disease biology models, and provided vast
database of highly consistent data about the biology of disease and software tools to use it.
The open innovation strategy was also adopted by GSK which has removed its IP
restrictions for promoting research in the area of neglected diseases like malaria. GSK has
made available 13,500 malaria compounds for open research. GSK has also released
genomic & protein expression profiling data for over 300 cancer cell lines via the NCI’s
cancer Bioinformatics Grid™ for academia to mine. To fully explore the potential of drug
repurposing, a pharma-academia integration effort was launched through CTSA
Pharmaceutical Assets Portal. It now includes 350 researchers from a number of
pharmaceutical companies (Pfizer, Merck, GSK, Novartis, Genentech, Abbott, Eli Lilly,
AstraZeneca) and 45 universities including University of California Davis, Oregon H&S
University, University of Washington, University of Pennsylvania, and the University of
Chicago probing 150 disease targets.
In addition to these, a number of multimillion dollar investments have been made by the
pharmaceutical giants at a number of academic institutions (GSK-Harvard, $50 million
Pfizer-University of California, $9.5 million, Pfizer and University of Pennsylvania, $15
million, to further the basic understanding of systems biology pathways related to human
diseases. These open innovation models is a strategic paradigm shift in overcoming
pharma’s long held NIH, “Not Invented Here” syndrome [30], and the realization that the
task at hand is too large for any one institution, and the collective wisdom of academia and
pharma is critical to combat human diseases and suffering.
Protection of Intellectual Property
One of the fundamental tenets of academic research is that the results are to further scientific
knowledge by publishing in peer reviewed journals. Until the 1980s, the government owned
intellectual property (IP) from federally funded research, and this research went into public
domain in the form of publications and presentations without IP rights. This inhibited the
industry from immediately transforming the research ideas coming out of academia into
marketable products. The passage of Bayh-Dole Patent and Trademark Act of 1980 was
intended to promote comercialization of inventions resulting from federally funded research.
This act provided an incentive to the inventors to use patents to protect their IP. Offices of
technology transfer were soon created widely across academic institutions, followed by an
increase in patent applications from federally-funded research. Technology transfer offices
continue to assist in the commercialization of research results funded primarily by the
government for the welfare of the public. Tasks required by this role include the preparation
of confidentiality agreements, materials-transfer agreements, licensing out technology,
examining IP, and collaborative agreements with industry. The technology transfer from
academia to industry entails pre-discovery data sharing, experimental data for testing
computational compound prediction and pharmacological models. An increase in academic/
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industry relationship is also reflected in establishment and success of the Association of
University Technology Managers (AUTM). The AUTM reported an increase in scientific
patents issued to universities from 890 to 2120 in the post-Bayh-Dole decade. Under the
auspices of the National Science Foundation, Kauffman Foundation, University of Illinois
and others, the University-Industry Demonstration Partnership (UIDP) program was
launched in 2006 to nourish and expand collaborative partnerships between university and
industry in the United States. The UIDP has developed Turbo Negotiator, a software tool, to
guide both sides to agreement on nature of project. India’s Academia Industry Interaction
Project is along the same vein, and has created a National database to promote and facilitate
pharmaceutical research through government-academia-industry partnership.
With regards to the results coming out of the academic HTS labs including those of the
MLSCN/MLPCN, the IP may lie in the use but not in the composition of matter. This is
because the majority of chemical libraries used by academic HTS labs are in the public
domain. Even though the MLPCN is inching more towards a dedicated chemistry-driven
effort in following up with the screen actives with IP potential, the NIH Roadmap initiative
mandates that the research results of the sponsored research be deposited in the public
domain through PubChem, with at best a 6 month hold on public disclosure. This does not
give enough time to fully explore the chemistry around the putative probe to make it
commercially attractive. Furthermore, most academic technology transfer offices are unable
to extract the IP potential of research coming out of the academic labs, and may not have the
experience or the necessary tools to prose-cute and defend IP rights. Many times, the
academic investigator approaches pharma to gain access to a tool compound for use in his/
her research and signs a Material Transfer Agreement with terminology such as, “recipient
hereby grants to the company a non-exclusive, worldwide, royalty-free, paid-up license,
with the right to sublicense, under any patent or other IP rights covering any use of any of
the Materials or derivatives arising from Requester’s research there with”. The academic
investigator should be aware of ironclad clauses like this which would permanently exclude
them from reaping the benefits of their research. Another classic example of academia’s IP
inexperience is exemplified by COX-2 story. The University of Rochester School of
Medicine and Dentistry published and filed for a patent in 1992 where in it claimed for the
usefulness of a COX-2 inhibitor in pain management. The same year, Merck and Searle
launched COX-2 programs and launched hugely profitable Celebrex and Vioxx in 1998. The
University filed a suit against Searle (Pfizer) in the year 2000, but eventually lost in the US
Supreme Court “because the inventors here simply failed to take the last critical step of
actually isolating a compound, or even developing a process through which one of skill
would be directly led to such a compound, this patent involves ’little more than a research
plan’” the court concluded. This illustrates the fact of not to rush to patent prematurely, and
this requires effective guidance from a well experienced technology transfer office. For spin-
off and incubator companies around academic innovations, careful thought must be given at
the outset whether to license a technology or product, or build a company around it. Given
that 95–97% of projects result in no licensable IP, the technology transfer offices have an
incredible responsibility in navigating academic research into a profitable enterprise.
A Roadmap for Successful Drug Discovery in Academia
The stochastic nature of screening for probes is now a recognized discipline in academia.
Each of the academic screening centers, with different specializations, has the potential to
develop to a level of maturity and robustness to contribute meaningfully towards
development of chemical probes in the era of chemical genomics. In the pharmaceutical
sector, new lead discovery has transformed over the years from being an art into a robust
scientific discipline. Having spent a collective number of decades in the pharmaceutical
sector, our perspective on drug discovery in academia is a mix of apprehension and
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appreciation. Academia’s endeavor in the arena of drug discovery is a Mount Everest in the
making, and requires careful nurturing to make it a successful reality (Table 8).
The core strength of academia is in basic and mechanistic biology, and the drug discovery
efforts need to be built on this solid platform. Pharmaceutical industry’s best practice of
matrix-based multidisciplinary team approach should be implemented in the public sector.
This approach should formulate the project goals and milestones by laying out a critical
project management path with industry-experienced project managers. It is important to
convey the message that the PI is in driver’s seat and seek strong, healthy collaborations. At
the very outset, draft target hypothesis and validation criteria, HTS assay design, validation,
readiness and implementation, active-hit-lead definitions, data analysis routines, secondary
and counter screens to address selectivity and pharmacokinetic issues, and work towards a
collaborative venture. A workstation-based, state-of-the-art screening facility should be
established with pharma-trained personnel. Personnel from the PI’s lab should be made part
of the project team in transferring and validating the bench-top assays into the HTS lab. This
is a critical step in the assay transfer process, because the PI’s bench-top assay may not be as
adequately robust or reproducible enough for the stringency of HTS. Since the success of
any HTS campaign in finding a target-specific probe is dependent on the assay design and
on the quality of the chemical library, best possible assay design should be favored over
what has been developed at the origination lab, and a high quality diverse chemical library
should be used. Institutional chemistries are equivalent of the corporate crown jewels. Every
possible effort should therefore be made to add the institution’s own legacy chemistries into
the HTS chemical archives by advocating the novelty and uniqueness of these chemistries,
therapeutic relevance, and the value of serendipity in finding the unexpected. This could be
achieved by emphasizing the fact that any IP that comes out from testing the institutional
chemistries lies with the PI who made the compounds. Because of the suspect authenticity
and the quality of the cell lines used in the PI’s lab, it is strongly advocated that cell lines for
use in cell-based assays be purchased from commercial sources. If commercial sources are
unavailable, it is important to ascertain the imported cell lines are not contaminated, using a
quarantine cell-culture lab. An experienced medicinal chemist’s intuition is critical for the
success of any probe discovery endeavor, and a competent medicinal chemist either from
one’s own institution or a collaborating institution must be recruited early on to carry data
mining, to ascertain chemical tractability and early SAR by commerce or synthesis. The
personnel from the technology transfer and commercialization office must be brought into
the project as soon as the target hypothesis has been drafted to ensure that the IP rights are
adequately clarified, protected and nurtured. For the probe discovery and development
initiatives in academia to be successful, the projects need to be actively managed, to prevent
an exercise in futility. New lead discovery against therapeutic targets, especially those
involving the rare and neglected diseases, is indeed a Mount Everestonian size task, and
requires diligent implementation of pharmaceutical industry’s best practices for a successful
outcome.
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Drug discovery project progression from basic research to probe development.
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Generalization of Academia vs. Industry in terms of (1) risk tolerance vs. (2) affected patient
population. Each dot represents an HTS campaign. This is a hypothetical generalization of
the relationship between risk and reward against investment, not based on actual data. Black
dot = Private domain HTS, Grey dot = Public domain HTS. Size of dot = Dollars spent or
resources allocated on a project.
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Industry level drug discovery in the public domain. The Molecular Libraries Probe Centers
Network (MLPCN) has brought together critical facets of the drug discovery process to the
public, giving open access to comprehensive compound screening and probe development,
advancing research through public data sharing via Pubchem.
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Example assay comparison for determining assay sensitivity for high throughput screening
(HTS), Tetrazolium-based MTS versus ATP quantitation of cell viability. Breast
adenocarcinoma cells (MCF-7 derivative) were seeded at a range of 4–125,000 cells per
well, followed by cell viability assessment by MTS and ATP quantitation assays. The
characteristics of the homogenous ATP-based assay were superior to the MTS assay, and the
improved sensitivity for measuring low numbers of cells (below 2,000 cells/well) confirmed
that the ATP-based assay method was more suitable for HTS.
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Table 1
The Molecular Libraries Probe Production Centers Network (MLPCN)
MLPCN Center Director Function Services
Broad Institute of MIT and
Harvard Stuart Schreiber
Comprehensive Centers Provide services covering ssays, cheminformatics/informatics, and medicinal chemistry.
Sanford/Burnham Institute John Reed
NIH Chemical Genomics Center Chris Austin
Scripps Research Institute Hugh Rosen
Johns Hopkins Min Li
Specialized Screening Centers Handle specialized types of assays includinghandling assay informatics.Southern Research Institute Colleen Jonsson
University of New Mexico Larry Sklar
University of Kansas Jeffrey Aube
Specialized Chemistry Centers
Focus on providing medicinal chemistry and
cheminformatics support for performing structure-
activity relationships that is typically needed to
produce useful chemical probes from screening hits.
Vanderbilt University Craig Lindsley
The most prominent public domain HTS resource of the past decade was the Molecular Libraries Screening Centers Network (MLSCN) and its
successor, the Molecular Libraries Probe Production Centers Network (MLPCN). The MLSCN was a national high-throughput biological
screening resource that was launched on June 15, 2005, and operated as a pilot phase for three years, replaced in June 2008 by the MLPCN. While
the MLSCN consisted of ten similar screening centers, the MLPCN is composed of three different types of centers: comprehensive centers,
specialized screening centers, and specialized chemistry centers.
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Table 2
The Critical Path of MLPCN Screening
Step Requirement or Cutoff Location
Assay development & validation Reproducible assay Assay Principal Investigator
Application to MLPCN Valuable/novel target Assay Principal Investigator
Primary assay (HTS) <10 µM MLPCN Screening Center
Secondary Assay/Dose Response IC50<1 µM MLPCN Screening Center
Counterscreen assay Selectivity >30× Assay Principal Investigator
Chemistry/SAR Best probe Specialized Chemistry Center or Comprehensive Screening Center
The progress of an assay to and through the MLPCN follows a critical path of steps containing cutoffs for potency, dose response, and selectivity.
Following the basic research efforts of a principle investigator (PI), an assay is developed to assay a novel or interesting target [8]. The PI applies
to have the assay adapted to a high throughput screen through an MLPCN funding mechanism. If the assay and/or target are novel, interesting, and
amenable to HTS, the MLPCN will import the assay to one of the production phase MLPCN screening centers. . The primary assay will then be
performed at the MLPCN screening center, testing anywhere from 50,000 to 500,000 small molecules in the MLPCN compound library at 10 µ M
to identify active compounds (actives).. These actives are then subjected to secondary screening, where they are tested at a range of four log
concentrations, to confirm the active and to identify an IC50 for the compound in the assay. Compounds with submicromolar IC50s (<1 µM)
proceed to counter screening and further development into a probe. Data is shared with the public through PubChem.
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Table 4
Academic High Throughput Screening Centers
Institution Chemical Library Size Director/Contact Website
Havard Medical School 101–150K Marcie Glicksman www.hcnr.med.harvard.edu/
Broad Institute of MIT and Harvard 500,000 Michael Foley www.broad.mit.edu/node/139
Columbia University Medical Center 118,000 James Rothman www.columbia.edu
Emory University 200,000 Haian Fu www.pharm.emory.edu
Harvard Medical School 250,000 Caroline Shamu iccb.med.harvard.edu
Johns Hopkins University 180,000 Min Li www.hopkinschemcore.org
National Cancer Institute 101–150K James McMahon home.ncifcrf.gov/mtdp/index
NIH Chemical Genomics Center 500,000 Jim Inglese www.ncgc.nih.gov
Ordway Research Institute 101–150K Graham Brock www.ordwayresearch.org/target
Sanford/Burnham Institute 500,000 John Reed bccg.burnham.org
Scripps Research Institute 500,000 Peter Hodder mlpcn.florida.scripps.edu
Southern Research Institute 500,000 Lucille White www.southernresearch.org/research/hts-center
St Jude Children’s Research Hospital 500,000 Taosheng Chen www.stjude.org
Stanford University 130,000 David Solow-Cordero htbc.stanford.edu
University of Cincinnati 250,000 Ruben Papoian www.drugdiscovery.uc.edu
University of Illinois 200,000 Chen Zhang www.scs.uiuc.edu/htsf
University of Kansas 171,736 Rathnam Chagaturu www.hts.ku.edu
University of New Mexico 231,000 Larry Sklar nmmlsc.health.unm.edu
University of Pennsylvania 218,000 Scott Diamond www.seas.upenn.edu/~pcmd/hts
University of Pittsburgh 300,000 John Lazo www.upddi.pitt.edu
University of Washington 101–150K Timothy Martins depts.washington.edu/uwhts/
University of Wisconsin Madison 105,000 F. Michael Hoffmann www.hts.wisc.edu
UT Southwestern Medical Center 200,000 Michael Roth www.utsouthwestern.edu
Vanderbilt University 260,000 David Weaver www.mc.vanderbilt.edu/centers/mlpcn/index
Walter & Eliza Hall Institute 101–150K John Parisot www.biotechcentre.net.au/HTCS/htcs
Washington University 140,000 Jayne Marasa mic.wustl.edu/Cores/HighThroughputCore
The past decade has seen a rise in the number and size of academic HTS centers, containing large compound libraries of 100,000 or more
compounds.
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Table 5
Common Assay Methodologies for HTS in The Public Domain
Screen Assay readout Summary Example application
Biochemical
FP Fluorescence polarization, ratiometric readout ofpolarized light alteration. Receptor-ligand interactions
FRET Fluorescence resonance energy transfer. Kinase activity measurement
TR-FRET Time-resolved fluorescence resonance energytransfer. Kinase activity measurement
Cell based
RNA interference Small interfering RNA (siRNA) mediatedsilencing of genes. Genome siRNA library
High content analysis Quantification of protein location andexpression by microscopy-based imaging. Fluorescently labeled antibodies
Fluorescence - kinetic Rapid detection of fluorescence from calcium-or voltage-sensitive dyes (FLIPR).




Detection of phenotypic cellular changes, and





Real-time detection of specificity, affinity,





Measurement of protein-protein interaction and






Bioluminescence Detection of bioluminescence by reporter geneassays. Luciferase detection
ECL Electrochemiluminescence assay. ELISA based assays
Fluorescence - chromophores Detection of flurescent probes and antibodiesbinding to cellular components. Alexafluor detection
Fluorescence - proteins Fluorescing protein detection from reporter geneassays & protein-protein interactions.
Green fluorescent protein (GFP)
detection
PCA Protein complementation assay, detectsinteracting proteins. Luciferase, B-lactamase, GFP
Academic and government HTS centers have many of the same capabilities and technologies as the pharmaceutical industry, enabling equal
capacity for primary, secondary and tertiary screening, covering a wide range of assay methodologies, ranging from conventional biochemical and
cell-based assays to novel label-free high throughput methods.
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Table 6
Characteristics of an Ideal Probe*
Parameter Characteristic Feature
Chemistry
Proven chemical identity with a defined structure
Close analogs with a clear and quantifiable structure-activity relationship over a 2–3 log drug
concentration range
More than one chemotype with an analogous activity profile
Efficacy and Potency
Biochemical target specificity or -selectivity around 3 orders of magnitude, within class
Pharmacological profile against targets within class and across related biochemical classes to be 2–3
orders of magnitude lower
Clear sigmoidal dose-activity relationship
Maximal efficacy within 2 log concentration range
Potency at submicromolar (biochemical) or micromolar (cellular) level
Target selectivity established within the cellular context
Mechanism of action defined and established without ambiguity
Pharmacokinetic and
pharmacodynamic properties
Preferred, but not necessary, ADMET profile, adherence to Lipinski rules, membrane permeability,
aqueous solubility, etc.
Intellectual property rights Preferred, but not necessary
*
The characteristics of a successful lead are distinctly different from the ones defined here for a chemical probe. Medicinal chemistry optimization
of a probe meeting the criteria listed here should result in the development of lead(s) with ideal PK/PD properties and clear IP rights that are
paramount for a lead with tractable chemistry.
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Table 7
Pharmaceutical Collaborations and Research Extensions
Pharma R&D Units
Novartis Institutes of Biomedical Research
GSK Centers of Excellence for Drug Discovery
Pfizer Bio-therapeutics and Bio-Innovation Center
Pfizer CTSA Pharmaceutical Assets portal
Eli lilly Phenotypic Drug Discovery (PD2) Initiative
Merck Merck-Sage Bionetworks
Novartis-MIT Center for Continuous Manufacturing
Lilly-Melbourne Lilly-Melbourne Academic Psychiatry Initiative
Merck External Basic Research
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Table 8
Roadmap for Successful High Throughput Screening
• The Entire Target Universe is at Academia’s Doorstep to Explore, Conquer and Eradicate Diseases Afflicting Humanity. For this to
happen-
• Continue strong therapeutic biology focus
• In-depth biology is academia’s GREATEST strength
• Establish a state-of-the art screening facility with pharma trained personnel
• Maintain a high ‘quality’ & ‘diverse’ chemical library, and expand based on project scope
• Cell lines- bring them fresh from a commercial source
• Use cutting edge tools and technology formats
• Make medicinal chemistry involvement a prerequisite
• Manage IP issues with appropriate balance between public sharing and commercial exploitation
• Establish secondary and tertiary assays to determine selectivity and specificity
• Encourage collaborative interactions to drive probe discovery
• Actively manage projects, a pharma best practice, with trained project coordinators, with clear goals, timelines and go/no-go criteria
• Make the Principal Investigator in the driver’s seat
• Engage in training the next generation of scientists
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